Sunday, September 24, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Cancer

Boston University enters research agreement with Janssen

March 23, 2016
in Cancer
0
Share on FacebookShare on Twitter

(Boston)–In an effort to accelerate disease interception approaches to the management of chronic obstructive pulmonary disease (COPD) and lung cancer, Boston University School of Medicine (BUSM) has entered into a $10.1 million research agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies. Together with the Janssen Disease Interception Accelerator and Oncology Therapeutic Area, scientific teams will analyze data from the Detection of Early Lung Cancer Among Military Personnel (DECAMP) consortium, a multidisciplinary translational research program, to advance the development of targeted therapeutics for the interception of COPD and lung cancer.

"Through the identification of molecular biomarkers, we see an opportunity to screen people at risk for COPD and lung cancer and predict those who may be progressing towards disease so that we can intercede and intercept disease progression," explained Avrum Spira, MD, MS, professor of medicine, pathology and laboratory medicine at BUSM and principal investigator of the grant. "Working with samples from the DECAMP study and together with Janssen scientists, we hope to advance our ability to identify and understand molecular biomarkers that will aid in the discovery and development of more targeted therapies in the future for these devastating lung diseases."

As part of the four-year collaboration, research teams at BUSM and Janssen will collaborate to define baseline and longitudinal disease profiles in COPD at the transcriptomic level, including extensive imaging analysis and integration of clinical data parameters, in an effort to apply targeted therapeutic intervention in COPD. The teams will also focus on characterizing the transcriptomic alterations associated with early progression of lung cancer. The Janssen-sponsored research agreement will support expansion of the consortium and pursuit of additional molecular biomarkers that will enable development of disease interception approaches focused on COPD and lung cancer.

COPD, the third leading cause of death in the US, is a chronic progressive respiratory disease associated with tobacco smoking for which no effective therapies exists to reverse or halt disease progression. Lung cancer is the leading cause of cancer deaths in the United States and the world, with cigarette smoking as its major cause. The number of lung cancer-related deaths has remained essentially unchanged over the last three decades, in part because of the inability to detect lung cancer at its earliest–and potentially–curable stage. Military personnel and veterans, compared with the general population, have higher rates of lung cancer and COPD caused by smoking and exposure to other substances known to cause cancer, such as radon, asbestos, fuel exhaust and other battlefield emissions.

Spira and his colleagues, including Marc Lenburg, PhD, and George O'Connor, MD, professors of medicine at BUSM, are working to develop and validate airway genomic biomarkers that can be used for the early detection of COPD and lung cancer. In addition, the team will also investigate the potential role of the immune system in mediating the development of lung cancer. Further, they are working to identify molecular biomarkers that associate with clinical outcome in patients with COPD and lung cancer. "By determining which biomarkers are involved, we can then target medicines to treat COPD and lung cancer on a molecular level," added Spira who is also director of the BU Cancer Center and a pulmonologist at Boston Medical Center.

Spira is the principal investigator of a national research study funded by the Department of Defense (W81XWH-11-2-0161) called Detecting Early Lung Cancer Among Military Personnel (DECAMP), a multicenter consortium involving four military hospitals and seven Veterans facilities.

###

Media Contact

Gina DiGravio
ginad@bu.edu
617-638-8480
@BostonUNews

http://www.bmc.org

Share25Tweet16Share4ShareSendShare
  • Null results research now published by major behavioral medicine journal

    1038 shares
    Share 415 Tweet 260
  • New findings on hair loss in men

    68 shares
    Share 27 Tweet 17
  • Tirzepatide more effective in blood sugar control and body weight loss than semaglutide, shows meta-analysis of 22 studies

    64 shares
    Share 26 Tweet 16
  • Astronomers discover newborn galaxies with the James Webb Space Telescope

    64 shares
    Share 26 Tweet 16
  • Chromosome-scale genome sequence of Suaeda glauca sheds light on salt stress tolerance in halophytes

    63 shares
    Share 25 Tweet 16
  • ISSCR Kicks off São Paulo International Symposium today in Ribeirão Preto, Brazil

    64 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Null results research now published by major behavioral medicine journal

Corning® launches Videodrop, revolutionizing real-time nanoparticle detection and analysis

Grant awarded to University of Louisville law professor will fund climate adaptation project

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 208 other subscribers

© 2023 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2023 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In